Vaso Corp Reports Record $89.1M Annual Revenue, $1.6M Net Income; Q4 Profit Halved by Impairment
summarizeSummary
Vaso Corporation announced its financial results for the fourth quarter and full year 2025. For the full year, the company achieved record revenue of $89.1 million, a 3% increase year-over-year, and net income rose to $1.6 million from $951 thousand in 2024. Cash flow from operations was strong at $9.3 million, with $35.1 million in cash and equivalents. However, Q4 2025 saw revenue remain flat at $27.0 million, and net income decreased to $1.1 million from $2.1 million in Q4 2024, primarily due to a goodwill impairment write-down and increased SG&A expenses. The full-year results indicate continued top-line growth and profitability, which is positive for a company of Vaso's market capitalization. The strong cash position also provides financial stability. However, the significant decline in Q4 net income, driven by a goodwill impairment and higher operating costs, could raise concerns about recent operational efficiency and asset valuation, potentially impacting investor sentiment. The sale of its healthcare IT business unit in November 2025 also represents a strategic shift. Traders will monitor future quarters for trends in profitability, especially the impact of the business unit sale and whether the goodwill impairment was a one-off event or indicative of broader asset valuation issues.
At the time of this announcement, VASO was trading at $0.17 on OTC in the Life Sciences sector, with a market capitalization of approximately $29.3M. The 52-week trading range was $0.11 to $0.21. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.